Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis (Q45404222)

14 December 2017

0 references

Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis (English)

1 reference

14 December 2017

1 reference

1 reference

Zhe Huang

1 reference

14 December 2017

Fang Liu

series ordinal

1 reference

14 December 2017

publication date

1 May 2014

1 reference

14 December 2017

1 reference

14 December 2017

1 reference

14 December 2017

1 reference

14 December 2017

page(s)

7459-7465

1 reference

Epidemiology of pancreatic cancer: an update

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Pancreatic cancer stem cell biology and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Systematic reviews of diagnostic test accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

CA 242 is a new tumor marker for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Utility of tumor markers in determining resectability of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

The discovery, biology, and drug development of sialyl Lea and sialyl Lex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Pyruvate kinase type M2 and its role in tumor growth and spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

21 January 2018

12 December 2020

Molecular markers of early pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

The diagnostic odds ratio: a single indicator of test performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1995-9

Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer

21 January 2018

1 reference

12 December 2020

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

1 reference

12 December 2020

Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer

1 reference

12 December 2020

Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer

1 reference

12 December 2020

Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head

1 reference

12 December 2020

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9

1 reference

12 December 2020

CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer

1 reference

12 December 2020

Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer

1 reference

12 December 2020

Novel serum tumor marker, RCAS1, in pancreatic diseases

1 reference

12 December 2020

The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma

1 reference

12 December 2020

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

1 reference

12 December 2020

10.1007/S13277-014-1995-9

Identifiers

DOI

1 reference

Dimensions Publication ID

14 December 2017

1012019910

0 references

1 reference